Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Shareholder Meeting (August 2024)
10 slides from Radiopharm Theranostics's shareholder meeting presentation, August 2024
Slide 1: EGM Presentation – August 2024
EGM Presentation – August 2024 RADIOPHARM THERANOSTICS LTD 2024 1
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN
Slide 3: RAD is at the cutting edge of radiopharmaceuticals, a transformative modality within cancer treatment
RAD IS AT THE CUTTING EDGE OF RADIOPHARMACEUTICALS, A TRANSFORMATIVE MODALITY WITHIN CANCER TREATMENT 1 Differentiated Within Radiopharmaceuticals • Clinical-stage company with deep pipeline of radiotherapeutic assets pursuing novel targets, leveraging insights from ADCs, using innovative targeting
Slide 4: Lantheus Strategic Investment
LANTHEUS STRATEGIC INVESTMENT Lantheus Holdings Inc (LNTH.NASDAQ, market cap approximately US$7Bn) is a global leader in the development, manufacture and commercialisation of diagnostic and therapeutic radiopharmaceutical products with offices in Massachusetts, New Jersey, Canada and Sweden. Shares
Slide 5: Radiopharmaceuticals deliver radiation directly to cancer cells
RADIOPHARMACEUTICALS DELIVER RADIATION DIRECTLY TO CANCER CELLS Building Blocks of Considerations Radiopharmaceuticals Targeting Molecule Serum half-life, immunogenicity, tumor uptake (high affinity small and retention, plasma clearance (especially via molecule, peptide or renal system) antibody) Ta
Slide 6: Expanding radiopharmaceutical targets and indications
EXPANDING RADIOPHARMACEUTICAL TARGETS AND INDICATIONS Novel Radiopharmaceutical Targets With Validated Biology beyond PSMA, SSTR2, FAPI PD-L1, HER2, (nanobodies); αVβ6 Integrin (peptide), fatty acid synthase (small molecule) Tuned Isotope Selection Lu177 (beta), Ac225 (alpha), Tb161 (beta + Auger) O
Slide 7: Company Pipeline
COMPANY PIPELINE TARGET & PROGRAM INDICATION Dx/Tx ISOTOPE PRECLINICAL PHASE I PHASE II NOTES MOLECULE PD-L1 NON-SMALL CELL RAD204 Therapy Lu177 Phase 1 enrolling in Australia, NCT06305962 LUNG CANCER (Nanobody) HER 2 BREAST / Ethics approval in Q3 2024 RAD202 Therapy Lu177 GASTRIC CANCER Phase 1 tr
Slide 8: Compassionate use and Imaging trials derisked clinical development: 172 patients already dosed
Compassionate use and Imaging trials derisked clinical development: 172 patients already dosed PRE-CLINICAL COMPASSIONATE USE PHASE 1 PHASE 1/2 PHASE 2/2b PHASE 2/3 Pivalate F18 n=17 2H2024 2026 Small n=24 Imaging n=30 n=150 molecule Imaging Phase 2a Imaging Imaging RAD 101 Integrins 2026 n=99 n= 9
Slide 9: Upcoming Milestones: data read-outs in the next 18-24 months
Upcoming Milestones: 4 data read-outs in the next 18-24 months 1H 2024 2H 2024 1H 2025 2H 2025 1H 2026 TARGET & PROGRAM INDICATION Dx/Tx ISOTOPE MOLECULE PD-L1 NON-SMALL CELL P1 in Aus RAD204 Therapy Lu177 read-out (Nanobody) LUNG CANCER HER 2 BREAST / RAD202 Therapy Lu177 P1 in Aus read-out (Nanobo
Slide 10: Radiopharm Theranostics Ltd 2024
RADIOPHARM THERANOSTICS LTD 2024 10
Radiopharm Theranostics — Shareholder Meeting (August 2024) on 6ix